2- (3- (pyridin- 2- ylmethoxy)pyrrolidin- 1- yl)- 5- (trifluoromethyl)benzoic acid

an endothelial lipase inhibitor; structure in first source

Also Known As:

XEN445

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 01/01/2020 - "XEN445 inhibited the self-renewal of cancer stem cells (CSCs) in vitro and TNBC tumor formation in vivo. " 01/01/2020 - "The present studies were aimed at determining how XEN445, a specific inhibitor targeting LIPG phospholipase activity, impacts on TNBC tumor formation and malignant features. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2020 - "We found that XEN445 preferentially inhibited the proliferation of LIPG-expressing TNBC cells but not LIPG-negative luminal breast cancer cells. "

1.	Phospholipases (Phospholipase)
2.	Phenobarbital (Luminal)